Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued on Tuesday.

Pulse Biosciences Trading Down 5.5 %

NASDAQ:PLSE traded down $1.04 during mid-day trading on Tuesday, hitting $17.74. The stock had a trading volume of 307,818 shares, compared to its average volume of 201,282. Pulse Biosciences has a 52 week low of $5.22 and a 52 week high of $22.69. The company has a 50 day simple moving average of $17.35 and a 200-day simple moving average of $14.91.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the prior year, the business earned ($0.19) EPS.

Institutional Trading of Pulse Biosciences

A number of institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after buying an additional 2,952 shares in the last quarter. Quest Partners LLC acquired a new stake in Pulse Biosciences during the second quarter valued at approximately $91,000. Bank of New York Mellon Corp grew its position in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Pulse Biosciences in the 1st quarter worth about $88,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.